pyrroles has been researched along with idelalisib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, DW; Brauer, PM; Hariharan, S; Leber, B; Oakes, CC; Oppermann, S; Shi, Y; Spaner, DE; Ylanko, J; Zúñiga-Pflücker, JC | 1 |
| Grant, FM; Gyori, D; Hawkins, PT; Lim, EL; Okkenhaug, K; Roychoudhuri, R; Shuttleworth, SJ; Spensberger, D; Stephens, LR | 1 |
2 other study(ies) available for pyrroles and idelalisib
| Article | Year |
|---|---|
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.
Topics: Adenine; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cellular Microenvironment; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Imaging, Three-Dimensional; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Quinazolinones; Reproducibility of Results; Signal Transduction; Stromal Cells; Sulfonamides; Sunitinib; Up-Regulation | 2016 |
Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
Topics: Aminopyridines; Animals; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Diphtheria Toxin; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Forkhead Transcription Factors; Gene Knockout Techniques; Humans; Lymphocyte Depletion; Macrophages; Male; Mice; Mice, Transgenic; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Primary Cell Culture; Purines; Pyrroles; Quinazolinones; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; T-Lymphocytes, Regulatory; Tumor Microenvironment | 2018 |